NAV

Furaltadone

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Furaltadone is indicated in combination with other drugs for the treatment of otitis media and externa.

Generic Name
Furaltadone
DrugBank Accession Number
DB16567
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
3D
Similar Structures
Weight
Average: 324.293
Monoisotopic: 324.106984251
Chemical Formula
C13H16N4O6
Synonyms
  • Furaltadona
  • Furaltadone
External IDs
  • 205-384-5
  • NSC-42388
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
OTOZAMBONFuraltadone (0.45 G/100ML) + Fludrocortisone (0.1 G/100ML) + Lidocaine (4 G/100ML) + Neomycin (0.375 G/100ML) + Polymyxin B (1 MU/100ML)LiquidAuricular (otic)บริษัท เสริมมิตรพาณิชย์ จำกัด จำกัด1980-01-012020-09-29Thailand flag
ออโตสามธงFuraltadone (0.45 G/100ML) + Fludrocortisone (0.1 G/100ML) + Lidocaine (4 G/100ML) + Neomycin (0.375 G/100ML) + Polymyxin B (1 MU/100ML)LiquidAuricular (otic)บริษัท เอส.เอ็ม.ฟาร์มาซูติคอล จำกัด จำกัด1990-09-17Not applicableThailand flag
เอส.เอ็ม. ออโตFuraltadone (0.45 G/100ML) + Fludrocortisone (0.1 G/100ML) + Lidocaine (4 G/100ML) + Neomycin (0.375 G/100ML) + Polymyxin B (1 MU/100ML)LiquidAuricular (otic)บริษัท เอส.เอ็ม.ฟาร์มาซูติคอล จำกัด2001-02-14Not applicableThailand flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
5X4V82ZN30
CAS number
139-91-3
InChI Key
YVQVOQKFMFRVGR-VGOFMYFVSA-N
InChI
InChI=1S/C13H16N4O6/c18-13-16(14-7-10-1-2-12(22-10)17(19)20)9-11(23-13)8-15-3-5-21-6-4-15/h1-2,7,11H,3-6,8-9H2/b14-7+
IUPAC Name
5-[(morpholin-4-yl)methyl]-3-[(E)-[(5-nitrofuran-2-yl)methylidene]amino]-1,3-oxazolidin-2-one
SMILES
[O-][N+](=O)C1=CC=C(O1)\C=N\N1CC(CN2CCOCC2)OC1=O

References

General References
  1. FDA Thailand: SM Oto (Fludrocortisone, Furaltadone, Lidocaine, Neomycin, Polymyxin B) Otic Liquid [Link]
ChemSpider
7831887
ChEMBL
CHEMBL1189513

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
LiquidAuricular (otic)
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.553 mg/mLALOGPS
logP0.15ALOGPS
logP0.73Chemaxon
logS-2.8ALOGPS
pKa (Strongest Basic)6.44Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count6Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area110.65 Å2Chemaxon
Rotatable Bond Count5Chemaxon
Refractivity76.84 m3·mol-1Chemaxon
Polarizability31.58 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-181.05334
predicted
DeepCCS 1.0 (2019)
[M+H]+183.41135
predicted
DeepCCS 1.0 (2019)
[M+Na]+189.79478
predicted
DeepCCS 1.0 (2019)

Drug created at February 08, 2021 20:31 / Updated at May 22, 2021 06:02